{"id":"pamiparib-capsule","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pamiparib is a PARP inhibitor that blocks the enzyme responsible for repairing single-strand DNA breaks in cancer cells. By inhibiting PARP, the drug causes accumulation of DNA damage, leading to cell death. It is particularly effective in tumors with homologous recombination deficiency (HRD), such as BRCA-mutated cancers.","oneSentence":"Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:33.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer (BRCA-mutated or HRD-positive)"},{"name":"Breast cancer (BRCA-mutated)"},{"name":"Gastric cancer (HRD-positive)"}]},"trialDetails":[{"nctId":"NCT03519230","phase":"PHASE3","title":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2018-05-14","conditions":"Ovarian Cancer","enrollment":224},{"nctId":"NCT03333915","phase":"PHASE1, PHASE2","title":"Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2016-12-21","conditions":"Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer","enrollment":128},{"nctId":"NCT03150810","phase":"PHASE1","title":"Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-06-28","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":139},{"nctId":"NCT05652283","phase":"PHASE2","title":"Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bai-Rong Xia","startDate":"2022-11-06","conditions":"Ovarian Cancer","enrollment":37},{"nctId":"NCT05573373","phase":"PHASE1","title":"Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2022-12-20","conditions":"Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT03933761","phase":"PHASE2","title":"Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy","status":"WITHDRAWN","sponsor":"Australia New Zealand Gynaecological Oncology Group","startDate":"2019-07-29","conditions":"Ovarian Cancer, Carcinosarcoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BGB-290"],"phase":"phase_3","status":"active","brandName":"Pamiparib capsule","genericName":"Pamiparib capsule","companyName":"BeiGene","companyId":"beigene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death. Used for Ovarian cancer (BRCA-mutated or HRD-positive), Breast cancer (BRCA-mutated), Gastric cancer (HRD-positive).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}